The HTAi PCIG Patient Preference Sub-Committee has initiated a project designed to improve the likelihood that patient preferences can and will be used more frequently in HTA decision-making. The initial step in the project is to conduct an assessment of the current landscape of HTA use of patient preferences in HTA decision-making, and interest in doing so if not currently doing so. Out of that assessment, the PPWG will facilitate a co-created patient preference study between multiple HTA’s in a case study, where observations about best practices and considerations for adoption will be made.
Alex Chambers Manager, Health Policy and Patient Access, Novartis Pharmaceuticals Canada
Moderator: HTAi PCIG PPWG representative, Barry D. Stein, President/CEO Colorectal Cancer Canada
HTAi PCIG PPWG co-chair, Barry Liden, VP Patient Engagement, Edwards Lifesciences to present HTA survey findings
HTA representatives to react to findings and share thoughts/responses to questions:
Jacoline Bouvy Technical Director, National Institute for Health and Care Excellence, NICE
Nicole Mittmann Chief Scientist/VP, Evidence Standards, Canadian Agency for Drugs and Technologies in Health
Laurie Lambert Lead, Real World Evidence Strategy, Evidence Standards, Canadian Agency for Drugs and Technologies in Health
Industry representative to react to findings and share thoughts/responses to questions